We confirm that R-CHOP is a good standard of care for most patients with diffuse large B-cell lymphoma, but raise the possibility that high-risk subgroups could benefit from the addition of a proteasome inhibitor to standard therapy, which could guide future research. Here, DDIT3 is linked to diffuse large B-cell lymphoma.